Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 112
- Registration Number
- NCT03760822
- Locations
- 🇫🇷
CH - Albi, Albi, France
🇫🇷Privee - Hopital Prive, Antony, France
🇫🇷CH -, Dunkerque, France
RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 54
- Registration Number
- NCT03745430
- Locations
- 🇬🇷
Agios Savvas Anticancer Hospital, Athens, Attiki, Greece
🇬🇷EUROMEDICA General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece
🇬🇷Aretaieio Hospital, Athens, Attiki, Greece
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03704077
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 66
- Registration Number
- NCT03694002
- Locations
- 🇺🇸
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States
🇺🇸Mercy Medical Center, Durango, Colorado, United States
🇺🇸Southwest Oncology PC, Durango, Colorado, United States
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT03689855
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 43
- Registration Number
- NCT03650764
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 164
- Registration Number
- NCT03560973
- Locations
- 🇮🇹
Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03527108
- Locations
- 🇺🇸
NYU Langone, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 430
- Registration Number
- NCT03520946
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Universitätsklinikum Leipzig, Leipzig, Germany
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Arkadiusz Z. Dudek, MD
- Target Recruit Count
- 34
- Registration Number
- NCT03502746
- Locations
- 🇺🇸
HealthPartners Institute Regions Cancer Care Center, Minneapolis, Minnesota, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.